Rxsight Valuation
| RXST Stock | USD 55.96 1.11 1.94% |
At this time, the company appears to be overvalued. Rxsight holds a recent Real Value of $50.06 per share. The prevailing price of the company is $55.96. Our model determines the value of Rxsight from analyzing the company fundamentals such as Return On Equity of -0.29, shares outstanding of 39.25 M, and Operating Margin of (0.36) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Rxsight's valuation include:
Price Book 13.6548 | Enterprise Value 2 B | Enterprise Value Ebitda (7.70) | Price Sales 22.1407 | Forward PE 172.4138 |
Overvalued
Today
Please note that Rxsight's price fluctuation is very steady at this time. Calculation of the real value of Rxsight is based on 3 months time horizon. Increasing Rxsight's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Rxsight's intrinsic value may or may not be the same as its current market price of 55.96, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 55.96 | Real 50.06 | Target 33.8 | Hype 55.6 | Naive 59.76 |
The intrinsic value of Rxsight's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Rxsight's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Rxsight helps investors to forecast how Rxsight stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Rxsight more accurately as focusing exclusively on Rxsight's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Rxsight's intrinsic value based on its ongoing forecasts of Rxsight's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Rxsight's closest peers.
Rxsight Investments |
|
Rxsight Valuation Trend
Knowing Rxsight's actual value is paramount for traders to make sound investment determinations. Rxsight's real value is not only important for the investor to make better decisions but also for a more accurate overall view of Rxsight's financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Rxsight's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.
Rxsight Market Cap
Rxsight is currently regarded as top stock in market capitalization category among its peers. Market capitalization of Health Care industry is at this time estimated at about 2.24 Billion. Rxsight totals roughly 2.24 Billion in market capitalization claiming about 100% of equities under Health Care industry.Rxsight Total Value Analysis
Rxsight is at this time projected to have valuation of 2 B with market capitalization of 2.24 B, debt of 3.01 M, and cash on hands of 128.62 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Rxsight fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
| 2 B | 2.24 B | 3.01 M | 128.62 M |
Rxsight Investor Information
About 84.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.03. Rxsight recorded a loss per share of 1.24. The entity had not issued any dividends in recent years. RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses used in cataract surgery in the United States and internationally. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. Rxsight operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 221 people. To find out more about Rxsight contact Ronald MD at 949 521 7830 or learn more at https://www.rxsight.com.Rxsight Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Rxsight has an asset utilization ratio of 48.8 percent. This implies that the Company is making $0.49 for each dollar of assets. An increasing asset utilization means that Rxsight is more efficient with each dollar of assets it utilizes for everyday operations.Rxsight Ownership Allocation
Rxsight owns a total of 39.25 Million outstanding shares. The majority of Rxsight outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Rxsight to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Rxsight. Please pay attention to any change in the institutional holdings of Rxsight as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Rxsight Profitability Analysis
The company reported the previous year's revenue of 89.08 M. Net Loss for the year was (48.61 M) with profit before overhead, payroll, taxes, and interest of 21.33 M.About Rxsight Valuation
The stock valuation mechanism determines the current worth of Rxsight on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Rxsight. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Rxsight based exclusively on its fundamental and basic technical indicators. By analyzing Rxsight's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Rxsight's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Rxsight. We calculate exposure to Rxsight's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Rxsight's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 53.8 M | 56.5 M | |
| Pretax Profit Margin | (0.55) | (0.52) | |
| Operating Profit Margin | (0.56) | (0.59) | |
| Net Loss | (0.55) | (0.52) | |
| Gross Profit Margin | 0.60 | 0.63 |
8 Steps to conduct Rxsight's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Rxsight's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Rxsight's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Rxsight's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Rxsight's revenue streams: Identify Rxsight's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Rxsight's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Rxsight's growth potential: Evaluate Rxsight's management, business model, and growth potential.
- Determine Rxsight's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Rxsight's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Rxsight Growth Indicators
Investing in growth stocks can be very risky. If the company such as Rxsight does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 34.5 M | |
| Forward Price Earnings | 172.4138 |
Rxsight Current Valuation Indicators
Valuation refers to the process of determining the present value of Rxsight and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Rxsight we look at many different elements of the entity such as Rxsight's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Rxsight's valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Rxsight's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Rxsight, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Rxsight's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Rxsight's worth.Additional Tools for Rxsight Stock Analysis
When running Rxsight's price analysis, check to measure Rxsight's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rxsight is operating at the current time. Most of Rxsight's value examination focuses on studying past and present price action to predict the probability of Rxsight's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rxsight's price. Additionally, you may evaluate how the addition of Rxsight to your portfolios can decrease your overall portfolio volatility.